Literature DB >> 14798

Phenylethanolamine N-methyltransferase and other enzymes of catecholamine metabolism in human brain.

T Nagatsu, T Kato, Y Numata, K Ikuta, M Sano.   

Abstract

The activities of tyrosine hydroxylase (TH), DOPA decarboxylase (DDC), dopamine beta-hydroxylase (DBH), phenylethanolamine N-methyltransferase (PNMT), and monoamine oxidase (MAO) with serotonin and phenylethylamine as substrates were measured in catecholaminergic regions of human brain from 10 controls and 3 patients with Parkinsonism. PNMT activity was detected in hypothalamus, thalamus and cerebellar nucleus of the control human brain, and was reduced in hypothalamus of Parkinsonian cases. Type A (with serotonin as substrate) and type B (with phenylethylamine as substrate) MAO activities were high in all brain regions with little individual variations in controls and Parkinsonian cases. TH activity was high in the controls and was markedly decreased, in substantia nigra, caudate nucleus, putamen and in pallidum, in all three cases of Parkinsonism. DDC activity in these regions was also decreased in 2 patients. However, one Parkinsonian case had only decreased TH and normal DDC activities. DBH activity in hypothalamus was also reduced in the Parkinsonian cases.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 14798     DOI: 10.1016/0009-8981(77)90193-0

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  17 in total

Review 1.  A possible pathophysiological role of tyrosine hydroxylase in Parkinson's disease suggested by postmortem brain biochemistry: a contribution for the special 70th birthday symposium in honor of Prof. Peter Riederer.

Authors:  Akira Nakashima; Akira Ota; Yoko S Kaneko; Keiji Mori; Hiroshi Nagasaki; Toshiharu Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2012-05-27       Impact factor: 3.575

Review 2.  Amine precursor amino acid therapy: from neurochemical basis to clinical aspects.

Authors:  T Nakajima
Journal:  Neurochem Res       Date:  1996-02       Impact factor: 3.996

3.  Astaxanthin protects against MPTP/MPP+-induced mitochondrial dysfunction and ROS production in vivo and in vitro.

Authors:  Dae-Hee Lee; Cuk-Seong Kim; Yong J Lee
Journal:  Food Chem Toxicol       Date:  2010-11-05       Impact factor: 6.023

4.  The activities of brain dopamine-beta-hydroxylase and catechol-O-methyl transferase in schizophrenics and controls.

Authors:  A J Cross; T J Crow; W S Killpack; A Longden; F Owen; G J Riley
Journal:  Psychopharmacology (Berl)       Date:  1978-10-31       Impact factor: 4.530

5.  DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness.

Authors:  W Birkmayer; G Birkmayer; H Lechner; P Riederer
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

6.  Striatonigral degeneration combined with Alzheimer's disease.

Authors:  K Kosaka; R Iizuka; Y Mizutani; T Kondo; T Nagatsu
Journal:  Acta Neuropathol       Date:  1981       Impact factor: 17.088

Review 7.  Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.

Authors:  Toshiharu Nagatsu; Ikuko Nagatsu
Journal:  J Neural Transm (Vienna)       Date:  2016-08-04       Impact factor: 3.575

8.  Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues.

Authors:  T Kato; M Okada; T Nagatsu
Journal:  Mol Cell Biochem       Date:  1980-11-20       Impact factor: 3.396

9.  Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.

Authors:  E Sofic; P Riederer; H Heinsen; H Beckmann; G P Reynolds; G Hebenstreit; M B Youdim
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

10.  Transplantation of cultured sympathetic ganglionic neurons into parkinsonian rat brain: survival and function of graft.

Authors:  N Nakao; T Itakura; Y Uematsu; N Komai
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.